Differentiation of Skull Base Chondrosarcomas, Chordomas, and Metastases: Utility of DWI and Dynamic Contrast-Enhanced Perfusion MR Imaging

References

1. 1.↵
   1. Kelly HR,
   2. Curtin HD

   . Imaging of skull base lesions. Handb Clin Neurol 2016;135:637–57 doi:10.1016/B978-0-444-53485-9.00030-1 pmid:27432686

   CrossRefPubMed
2. 2.↵
   1. Dolecek TA,
   2. Propp JM,
   3. Stroup NE, et al

   . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;1(Suppl 5):v1–49 doi:10.1093/neuonc/nos218 pmid:23095881

   CrossRefPubMed
3. 3.↵
   1. Almefty K,
   2. Pravdenkova S,
   3. Colli BO, et al

   . Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 2007;110:2467–67 doi:10.1002/cncr.23073 pmid:17894390

   CrossRefPubMed
4. 4.↵
   1. Pamir MN,
   2. Ozduman K

   . Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas. Eur J Radiol 2006;58:461–70 doi:10.1016/j.ejrad.2006.03.020 pmid:16631334

   CrossRefPubMed
5. 5.↵
   1. Mehta GU,
   2. Raza SM

   . Management of skull base metastases. Neurosurg Clin N Am 2020;31:659–66 doi:10.1016/j.nec.2020.06.013 pmid:32921360

   CrossRefPubMed
6. 6.↵
   1. Chaichana KL,
   2. Flores M,
   3. Acharya S, et al

   . Survival and recurrence for patients undergoing surgery of skull base intracranial metastases. J Neurol Surg B Skull Base 2013;74:228–35 doi:10.1055/s-0033-1342925 pmid:24436917

   CrossRefPubMed
7. 7.↵
   1. Laigle-Donadey F,
   2. Taillibert S,
   3. Martin-Duverneuil N, et al

   . Skull-base metastases. J Neurooncol 2005;75:63–69 doi:10.1007/s11060-004-8099-0 pmid:16215817

   CrossRefPubMed
8. 8.↵
   1. Mitsuya K,
   2. Nakasu Y,
   3. Horiguchi S, et al

   . Metastatic skull tumors: MRI features and a new conventional classification. J Neurooncol 2011;104:239–45 doi:10.1007/s11060-010-0465-5 pmid:21110218

   CrossRefPubMed
9. 9.↵
   1. Kremenevski N,
   2. Schlaffer SM,
   3. Coras R, et al

   . Skull base chordomas and chondrosarcomas. Neuroendocrinology 2020;110:836–47 doi:10.1159/000509386 pmid:32541136

   CrossRefPubMed
10. 10.↵
    1. Surov A,
    2. Meyer HJ,
    3. Wienke A

    . Apparent diffusion coefficient for distinguishing between malignant and benign lesions in the head and neck region: a systematic review and meta-analysis. Front Oncol 2019;9:1362 doi:10.3389/fonc.2019.01362 pmid:31970081

    CrossRefPubMed
11. 11.↵
    1. Gaddikeri S,
    2. Gaddikeri RS,
    3. Tailor T, et al

    . Dynamic contrast-enhanced MR imaging in head and neck cancer: techniques and clinical applications. AJNR Am J Neuroradiol 2016;37:588–95 doi:10.3174/ajnr.A4458 pmid:26427839

    Abstract/FREE Full Text
12. 12.
    1. Ota Y,
    2. Moore AG,
    3. Spector ME, et al

    . Prediction of wound failure in patients with head and neck cancer treated with free flap reconstruction: utility of CT perfusion and MR perfusion in the early postoperative period. AJNR Am J Neuroradiol 2022;43:585–91 doi:10.3174/ajnr.A7458] pmid:35361578

    Abstract/FREE Full Text
13. 13.
    1. Ota Y,
    2. Liao E,
    3. Capizzano AA, et al

    . MR diffusion and dynamic-contrast enhanced imaging to distinguish meningioma, paraganglioma, and schwannoma in the cerebellopontine angle and jugular foramen. J Neuroimaging 2021;32:502–10 doi:10.1111/jon.12959 pmid:34936708

    CrossRefPubMed
14. 14.↵
    1. Ota Y,
    2. Naganawa S,
    3. Kurokawa R, et al

    . Assessment of MR imaging and CT in differentiating hereditary and nonhereditary paragangliomas. AJNR Am J Neuroradiol 2021;42:1320–26 doi:10.3174/ajnr.A7166 pmid:33985956

    Abstract/FREE Full Text
15. 15.↵
    1. Ota Y,
    2. Liao E,
    3. Capizzano AA, et al

    . Diagnostic role of diffusion-weighted and dynamic contrast-enhanced perfusion MR imaging in paragangliomas and schwannomas in the head and neck. AJNR Am J Neuroradiol 2021;42:1839–46 doi:10.3174/ajnr.A7266 pmid:34446460

    Abstract/FREE Full Text
16. 16.↵
    1. Ota Y,
    2. Liao E,
    3. Kurokawa R, et al

    . Diffusion-weighted and dynamic contrast-enhanced MRI to assess radiation therapy response for head and neck paragangliomas. J Neuroimaging 2021;31:1035–43 doi:10.1111/jon.12875 pmid:34002429

    CrossRefPubMed
17. 17.↵
    1. Yeom KW,
    2. Lober RM,
    3. Mobley BC, et al

    . Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. AJNR Am J Neuroradiol 2013;34:1056–61, S1 doi:10.3174/ajnr.A3333 pmid:23124635

    Abstract/FREE Full Text
18. 18.↵
    1. Guan Y,
    2. Peck KK,
    3. Lyo J, et al

    . T1-weighted dynamic contrast-enhanced MRI to differentiate nonneoplastic and malignant vertebral body lesions in the spine. Radiology 2020;297:382–89 doi:10.1148/radiol.2020190553 pmid:32870135

    CrossRefPubMed
19. 19.↵
    1. Ginat DT,
    2. Mangla R,
    3. Yeaney G, et al

    . Diffusion-weighted imaging for differentiating benign from malignant skull lesions and correlation with cell density. AJR Am J Roentgenol 2012;198:W597–601 doi:10.2214/AJR.11.7424 pmid:22623576

    CrossRefPubMed
20. 20.↵
    1. Koontz NA,
    2. Wiggins RH 3rd.

    Differentiation of benign and malignant head and neck lesions with diffusion tensor imaging and DWI. AJR Am J Roentgenol 2017;208:1110–15 doi:10.2214/AJR.16.16486 pmid:28245145

    CrossRefPubMed
21. 21.↵
    1. Katonis P,
    2. Alpantaki K,
    3. Michail K, et al

    . Spinal chondrosarcoma: a review. Sarcoma 2011;2011:378957 doi:10.1155/2011/378957 pmid:21437176

    CrossRefPubMed
22. 22.
    1. Fromm J,
    2. Klein A,
    3. Baur-Melnyk A, et al

    . Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer 2018;18:849 doi:10.1186/s12885-018-4741-7 pmid:30143018

    CrossRefPubMed
23. 23.↵
    1. Bergh P,
    2. Kindblom LG,
    3. Gunterberg B, et al

    . Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000;88:2122–34 doi:10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO;2-1 pmid:10813725

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Santos P,
    2. Peck KK,
    3. Arevalo-Perez J, et al

    . T1-weighted dynamic contrast-enhanced MR perfusion imaging characterizes tumor response to radiation therapy in chordoma. AJNR Am J Neuroradiol 2017;38:2210–16 doi:10.3174/ajnr.A5383 pmid:28912284

    Abstract/FREE Full Text
25. 25.↵
    1. De Coninck T,
    2. Jans L,
    3. Sys G, et al

    . Dynamic contrast-enhanced MR imaging for differentiation between enchondroma and chondrosarcoma. Eur Radiol 2013;23:3140–52 doi:10.1007/s00330-013-2913-z pmid:23771600

    CrossRefPubMed
26. 26.↵
    1. Morales KA,
    2. Arevalo-Perez J,
    3. Peck KK, et al

    . Differentiating atypical hemangiomas and metastatic vertebral lesions: the role of T1-weighted dynamic contrast-enhanced MRI. AJNR Am J Neuroradiol 2018;39:968–73 doi:10.3174/ajnr.A5630 pmid:29650780

    Abstract/FREE Full Text
27. 27.↵
    1. Saha A,
    2. Peck KK,
    3. Lis E, et al

    . Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications. Spine (Phila Pa 1976) 2014;39:E1433–40 doi:10.1097/BRS.0000000000000570 pmid:25188594

    CrossRefPubMed